PROKIDNEY CORP.

ProKidney Corp., trading under the ticker DNAC, is a clinical-stage biopharmaceutical company focused on developing cell therapy treatments for chronic kidney disease. The company entered the public markets through a SPAC transaction in 2022, operating within the healthcare and biotechnology sector. The 8-K filing dated July 11, 2022, with accession number 0001193125-22-190652, reflects a corporate disclosure submitted during the company's early post-merger period as a publicly traded entity. ProKidney's therapeutic platform targets a significant unmet need in nephrology, positioning it within a growing field of regenerative medicine. Sign up for a full SpacDesk account to access complete filing histories, deal timelines, and sponsor data for DNAC and hundreds of other SPAC transactions.